South America's active pharmaceutical ingredients market is expected to exceed USD 24 billion by 2030, driven by rising healthcare investments and drug production.

Market Analysis

The market for Active Pharmaceutical Ingredients (API) in South America is growing due to an increase in the need for generic medications, a burgeoning healthcare industry, and heightened awareness regarding low-cost drugs. This region hosts both large pharmaceutical firms and small to medium-sized enterprises (SMEs), with Brazil, Argentina, and Chile serving as the principal markets. Although South America imports a considerable share of its APIs, there is a slow transition towards domestic production to satisfy the growing demand and lessen reliance on overseas suppliers. API regulations in South America differ by country, yet most nations adhere to standards established by the World Health Organization (WHO) and other global regulatory agencies. For example, Brazil's National Health Surveillance Agency (ANVISA) is responsible for regulating pharmaceutical products, including APIs, ensuring compliance with safety, quality, and efficacy requirements. Argentina features comparable regulatory bodies such as ANMAT (National Administration of Medicines, Food and Medical Technology). These regulatory agencies enforce Good Manufacturing Practices (GMP) standards and implement specific quality control protocols. Moreover, several countries in the area are striving to align with international standards to enhance local API production and boost exports. Active Pharmaceutical Ingredients (APIs) refer to the biologically active substances utilized in the production of pharmaceutical drugs. They are integral to delivering the therapeutic effects of the medication, and their manufacturing necessitates strict compliance with quality control and regulatory standards to guarantee safety and effectiveness. In South America, the need for APIs is propelled by an aging demographic, the escalation of chronic illnesses, and an increased emphasis on affordable healthcare. The rising occurrence of non-communicable diseases like diabetes, hypertension, and cancer has intensified the demand for APIs necessary for creating essential pharmaceuticals. Furthermore, the growing appetite for generic drugs is stimulating the market, as they provide a more affordable substitute to branded medications. According to the research report, " South America Active Pharmaceutical Ingredients Market Outlook, 2030," published by Bonafide Research, the South America Active Pharmaceutical Ingredients market is expected to reach a market size of more than USD 24.09 Billion by 2030. The Active Pharmaceutical Ingredients (API) market in South America offers considerable growth prospects fueled by rising healthcare needs, the growth of the pharmaceutical manufacturing industry, and improved access to healthcare. A significant opportunity lies in the progressive move towards domestic API production. Numerous countries in South America, including Brazil and Argentina, are allocating resources toward the creation and expansion of local manufacturing facilities to lessen their reliance on imports. The increasing demand for generic medications, propelled by escalating healthcare expenses and a stronger focus on economical treatments, further boosts the market's potential. Moreover, the escalation in the prevalence of chronic illnesses such as diabetes, cardiovascular conditions, and cancer generates ongoing demand for APIs, thereby further broadening the market. Regulatory systems throughout South America are progressively aligning with global standards to guarantee the safety, efficacy, and quality of APIs. Brazil’s ANVISA and Argentina's ANMAT implement regulations concerning API production and importation, including compliance with Good Manufacturing Practices (GMP), rigorous quality control measures, and routine inspections. Nations are also striving to synchronize their regulations with worldwide organizations like the WHO and the European Medicines Agency (EMA), which aids in fostering local production and export possibilities. The API market in South America is distinguished by a growing number of domestic pharmaceutical producers, an increasing demand for inexpensive generics, and heightened investments in infrastructure and technology. Several countries in the region are concentrating on enhancing their manufacturing capacities, quality assurance, and certifications to satisfy both local and global market requirements. Additionally, there is a growing emphasis on biopharmaceuticals and biotechnology-derived APIs, which provide high-value products with sophisticated therapeutic uses. The expansion of the API sector in South America yields beneficial effects on public health and the economy.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

Market Dynamic

Market DriversGrowing Demand for Generic Drugs:A significant factor influencing the Active Pharmaceutical Ingredients (API) market in South America is the escalating demand for generic drugs. As the healthcare system changes, increasing prices of branded medications have led to a substantial shift towards generic options. These medications, which possess the same active ingredients as their branded versions, are offered at a much lower cost, enhancing their availability to patients in developing nations. The drive for generics is particularly pronounced in South America, where the issues of affordability and healthcare accessibility are pressing concerns. Governments in nations such as Brazil and Argentina are committed to improving healthcare access, and generics are essential to this initiative. • Shift Toward Local API Production:An additional major factor propelling the API market in South America is the region's movement towards domestic production of APIs. Traditionally, numerous South American nations have depended on imports to fulfill their API requirements, but this has resulted in challenges regarding costs, supply chain interruptions, and reliance on overseas producers. In response, governmental bodies and private enterprises have begun allocating resources to develop local API production capabilities. Nations like Brazil and Argentina are concentrating on advancing their pharmaceutical manufacturing sectors through collaborations between public and private entities, aimed at diminishing dependence on international suppliers. Domestic API production presents several advantages, such as lower production costs, enhanced supply chain reliability, and a positive impact on the local economy through job creation Market ChallengesRegulatory Complexity and Compliance Issues:A significant challenge for the South American API market is dealing with the intricate and diverse regulatory frameworks across various nations. Each nation maintains its own standards and prerequisites for API production, and businesses must adhere to domestic regulations while also aligning with international norms. For example, Brazil’s ANVISA and Argentina's ANMAT enforce strict regulatory structures for API manufacturing and importation, which include GMP certifications. Nonetheless, the implementation of these regulations can differ, resulting in delays for product approvals and increased compliance costs. Regulatory discrepancies, particularly in smaller nations, can impede seamless market functions and deter investment in local API production. • Dependence on Imported APIs:Even though there are efforts to enhance local production, South America continues to depend significantly on imported APIs, particularly from countries like China and India, which lead the global API market. This reliance on external suppliers puts the region at risk of supply chain interruptions, price volatility, and geopolitical uncertainties. For instance, the COVID-19 pandemic underscored weaknesses in the global supply network, resulting in delays and shortages of essential API resources. While certain countries are striving to improve domestic API production, establishing the required infrastructure and expertise demands time, and dependence on imports continues to be an obstacle. Market TrendsShift Toward Local Production:In light of the challenges created by reliance on imports, various South American nations are concentrating on developing and strengthening local API production capacities. Governments are promoting investments in domestic pharmaceutical manufacturing via subsidies and grants. Brazil, for instance, has made progress toward diminishing dependence on imports through the creation of local production facilities and advancements in API manufacturing technology. This movement is anticipated to persist as nations aspire to secure drug availability, lower costs, and establish a competitive advantage in the worldwide API market. • Increasing Demand for Generic Drugs:The need for generic medications is increasing in South America due to rising healthcare demands from an aging population and a growing incidence of chronic illnesses such as diabetes, cardiovascular diseases, and cancer. Generics provide an economical approach to cut healthcare expenses, and as more patients and healthcare professionals gravitate toward affordable options, the demand for APIs used in the production of generic drugs is expanding. Governments in the region are also promoting the adoption of generics to enhance healthcare access.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant


Segmentation

Oncology is the quickest expanding application in the South American Active Pharmaceutical Ingredients (API) market as a result of the rising rate of cancer and heightened healthcare investments in targeted therapies. Oncology is rising to become the quickest expanding application within the South American Active Pharmaceutical Ingredients (API) market, mainly driven by the increasing incidence of cancer throughout the region. South America has experienced a significant rise in cancer cases attributed to aging populations, lifestyle changes, and environmental influences. This has led governments and healthcare systems to prioritize cancer management, resulting in a higher demand for oncology APIs. Cancer ranks as one of the primary causes of mortality in numerous South American nations, including Brazil, Argentina, and Chile. As per the World Health Organization (WHO), the incidence of cancer in Latin America is projected to grow in the forthcoming decades, further enhancing the pressing requirement for effective treatments. Consequently, the demand for oncology APIs, which are essential components in the synthesis of cancer medications, has increased significantly. The pharmaceutical sector has also moved towards more specialized, personalized treatment modalities, such as targeted therapies and immunotherapies, which necessitate advanced APIs. These treatments are specifically designed to hone in on cancer cells while minimizing harm to healthy cells, providing patients with more effective and less harmful treatment alternatives. South American nations are increasingly embracing these groundbreaking treatments, which are driving the expansion of the oncology API market. Moreover, government initiatives and heightened healthcare investments are further propelling the need for oncology APIs. Health ministries across South America are allocating funds toward cancer research and treatment infrastructure, including initiatives to promote affordable access to cancer therapies. Specifically, there is an emphasis on enhancing the availability of generics and biosimilars, which depend on oncology APIs to make treatments more accessible. The escalating cancer burden and the shift towards more sophisticated cancer therapies are establishing oncology as the fastest growing application in the South American API market. Biotech APIs represent the most rapidly expanding synthesis type in the South American Active Pharmaceutical Ingredients (API) market due to the rising demand for biologics and biosimilars, which provide more precise and effective treatments. Biotech APIs, which arise from biotechnological methods instead of traditional chemical synthesis, are swiftly emerging as the fastest-growing sector in the South American Active Pharmaceutical Ingredients (API) market. This expansion is primarily fueled by the increasing need for biologic medications and biosimilars, which are transforming the management of intricate diseases like cancer, autoimmune disorders, and chronic illnesses. Biotech APIs play a crucial role in producing biologics, which are large and intricate molecules that target specific disease pathways with a greater level of accuracy compared to conventional small molecule drugs. The growing incidence of chronic illnesses and cancers in South America has resulted in a substantial demand for biologic therapies, which are frequently more effective than standard treatments, particularly for conditions that prove challenging to manage with traditional medications. Furthermore, the rising acceptance of biosimilars, which serve as cost-effective substitutes for biologics, is additionally enhancing the demand for biotech APIs. Biosimilars are increasingly favored in South American nations as a way to provide patients with essential treatments at a decreased cost, all while maintaining efficacy. Governments in South America, particularly in nations such as Brazil and Argentina, have recognized the crucial role of biotechnology in enhancing healthcare results. They are channeling funds into research and development, cultivating a regulatory framework that promotes the production of biologics and biosimilars. Regulatory bodies like Brazil’s ANVISA are now aligning with global benchmarks for the approval of biotech goods, thereby fostering the growth of biotech API production within the region. In addition, the capability of biotech APIs to address a broad spectrum of diseases with fewer adverse effects compared to traditional medications is propelling their growing acceptance among healthcare providers. This momentum is speeding up the development of biotech API manufacturing in South America, establishing it as the fastest-growing segment within the region's API market. The fastest-growing category in the South American Active Pharmaceutical Ingredients (API) market is Merchant API manufacturing, driven by the escalating need for economical production and the increasing trend of outsourcing by pharmaceutical firms. Merchant API manufacturing has become the fastest-growing category in the South American Active Pharmaceutical Ingredients (API) market, primarily propelled by the rising demand for economical production and the growing trend of outsourcing by pharmaceutical firms. In this model, independent manufacturers create APIs that are available to various pharmaceutical companies, instead of being linked to a single drug product. This adaptability enables pharmaceutical companies to lower their production costs, sidestep the need to invest in costly manufacturing facilities, and concentrate on research and marketing. The increasing trend of outsourcing within the pharmaceutical sector is one of the primary factors contributing to the growth of merchant API manufacturing. Numerous pharmaceutical companies, especially in South America, are opting to collaborate with established merchant API manufacturers instead of developing their own internal production sites. This strategy aids in decreasing capital costs, optimizing operations, and alleviating risks related to manufacturing. Additionally, merchant manufacturers typically possess established proficiency in ramping up production, quality assurance, and adhering to regulations, which appeals to pharmaceutical firms aiming to reduce operational complications. Furthermore, South American nations such as Brazil, Argentina, and Chile are dedicated to fostering a competitive landscape for API manufacturing, which advantages merchant producers. These nations provide incentives, like tax reductions and subsidies, for domestic production and the export of APIs, thereby motivating independent manufacturers to widen their operations in the area. Moreover, merchant API manufacturers frequently have the capability to present a wide range of APIs across different therapeutic categories, addressing the increasing demand for generics and biosimilars, which are becoming more popular in South America because of their cost-effectiveness. The demand for more affordable and easily accessible medications in South America has risen, and merchant API manufacturers are strategically positioned to fulfill this necessity, rendering this manufacturing type the fastest-growing sector in the region’s API market.

Market Regional Insights

Brazil is at the forefront of the South American Active Pharmaceutical Ingredients (API) market due to its extensive pharmaceutical manufacturing capabilities, solid regulatory framework, and governmental backing for the healthcare sector. Brazil stands as the leading entity in the South American Active Pharmaceutical Ingredients (API) market, largely as a result of its wide-reaching pharmaceutical manufacturing infrastructure, strong regulatory framework, and government-supported initiatives aimed at enhancing the local healthcare sector. The nation hosts some of the largest pharmaceutical firms in Latin America, which have built a strong production base for API manufacturing. This infrastructure enables Brazil to fulfill domestic demand and simultaneously position itself as a significant exporter of APIs to other nations within the region. The Brazilian government significantly contributes to the pharmaceutical industry by implementing policies that encourage local API production, with the goal of lowering dependency on imports and fostering economic development. The National Health Surveillance Agency (ANVISA) is recognized for upholding stringent standards for the manufacturing and distribution of APIs, ensuring that Brazilian producers adhere to global quality benchmarks. This facilitates Brazilian API manufacturers in upholding elevated quality standards, thereby serving both local and international markets effectively. Additionally, Brazil’s emphasis on cultivating a strong generics market has further strengthened the API sector. As generics gain wider acceptance due to their cost-effectiveness, the demand for domestically manufactured APIs has increased, propelling market expansion. The Brazilian government’s dedication to delivering affordable healthcare to its citizens has led to a bustling generic drug market, with API production playing a pivotal role in satisfying this need. Moreover, Brazil’s vast and varied population generates a significant domestic market for pharmaceuticals, further solidifying the nation’s status as a leader in the South American API sector. The synergy of local manufacturing proficiency, governmental support, and rising demand for affordable healthcare positions Brazil as the largest contender in the region’s API market.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Discount offer

Companies Mentioned

  • Sun Pharmaceutical Industries Limited
  • Aurobindo Pharma Limited
  • Dr. Reddy’s Laboratories Limited
  • Lupin Limited
  • Pfizer Inc.
  • Novartis International AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Limited

Table of Contents

  • 1. Executive Summary
  • 2. Research Methodology
  • 2.1. Secondary Research
  • 2.2. Primary Data Collection
  • 2.3. Market Formation & Validation
  • 2.4. Report Writing, Quality Check & Delivery
  • 3. Market Structure
  • 3.1. Market Considerate
  • 3.2. Assumptions
  • 3.3. Limitations
  • 3.4. Abbreviations
  • 3.5. Sources
  • 3.6. Definitions
  • 4. Economic /Demographic Snapshot
  • 5. Global Active Pharmaceutical Ingredients Market Outlook
  • 5.1. Market Size By Value
  • 5.2. Market Share By Region
  • 5.3. Market Size and Forecast, By Application
  • 5.4. Market Size and Forecast, By Synthesis Type
  • 5.5. Market Size and Forecast, By Type of Manufacture
  • 5.6. Market Size and Forecast, By API Type
  • 5.7. Market Size and Forecast, By Drug Type
  • 6. South America Active Pharmaceutical Ingredients Market Outlook
  • 6.1. Market Size By Value
  • 6.2. Market Share By Country
  • 6.3. Market Size and Forecast, By Application
  • 6.4. Market Size and Forecast, By Synthesis Type
  • 6.5. Market Size and Forecast, By Type of Manufacture
  • 7. Market Dynamics
  • 7.1. Market Drivers & Opportunities
  • 7.2. Market Restraints & Challenges
  • 7.3. Market Trends
  • 7.3.1. XXXX
  • 7.3.2. XXXX
  • 7.3.3. XXXX
  • 7.3.4. XXXX
  • 7.3.5. XXXX
  • 7.4. Covid-19 Effect
  • 7.5. Supply chain Analysis
  • 7.6. Policy & Regulatory Framework
  • 7.7. Industry Experts Views
  • 7.8. Brazil Active Pharmaceutical Ingredients Market Outlook
  • 7.8.1. Market Size By Value
  • 7.8.2. Market Size and Forecast By Application
  • 7.8.3. Market Size and Forecast By Synthesis Type
  • 7.8.4. Market Size and Forecast By Type of Manufacture
  • 7.9. Argentina Active Pharmaceutical Ingredients Market Outlook
  • 7.9.1. Market Size By Value
  • 7.9.2. Market Size and Forecast By Application
  • 7.9.3. Market Size and Forecast By Synthesis Type
  • 7.9.4. Market Size and Forecast By Type of Manufacture
  • 7.10. Columbia Active Pharmaceutical Ingredients Market Outlook
  • 7.10.1. Market Size By Value
  • 7.10.2. Market Size and Forecast By Application
  • 7.10.3. Market Size and Forecast By Synthesis Type
  • 7.10.4. Market Size and Forecast By Type of Manufacture
  • 8. Competitive Landscape
  • 8.1. Competitive Dashboard
  • 8.2. Business Strategies Adopted by Key Players
  • 8.3. Key Players Market Positioning Matrix
  • 8.4. Porter's Five Forces
  • 8.5. Company Profile
  • 8.5.1. Aurobindo Pharma Limited
  • 8.5.1.1. Company Snapshot
  • 8.5.1.2. Company Overview
  • 8.5.1.3. Financial Highlights
  • 8.5.1.4. Geographic Insights
  • 8.5.1.5. Business Segment & Performance
  • 8.5.1.6. Product Portfolio
  • 8.5.1.7. Key Executives
  • 8.5.1.8. Strategic Moves & Developments
  • 8.5.2. Dr. Reddy’s Laboratories Limited
  • 8.5.3. Lupin Limited
  • 8.5.4. Sun Pharmaceutical Industries Limited
  • 8.5.5. Pfizer Inc.
  • 8.5.6. Novartis International AG
  • 8.5.7. Sanofi S.A.
  • 8.5.8. Teva Pharmaceutical Industries Limited
  • 8.5.9. AbbVie Inc.
  • 8.5.10. GlaxoSmithKline plc.
  • 9. Strategic Recommendations
  • 10. Annexure
  • 10.1. FAQ`s
  • 10.2. Notes
  • 10.3. Related Reports
  • 11. Disclaimer

Table 1: Global Active Pharmaceutical Ingredients Market Snapshot, By Segmentation (2024 & 2030) (in USD Billion)
Table 2: Top 10 Counties Economic Snapshot 2022
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: Global Active Pharmaceutical Ingredients Market Size and Forecast, By Application (2019 to 2030F) (In USD Billion)
Table 6: Global Active Pharmaceutical Ingredients Market Size and Forecast, By Synthesis Type (2019 to 2030F) (In USD Billion)
Table 7: Global Active Pharmaceutical Ingredients Market Size and Forecast, By Type of Manufacture (2019 to 2030F) (In USD Billion)
Table 8: Global Active Pharmaceutical Ingredients Market Size and Forecast, By API Type (2019 to 2030F) (In USD Billion)
Table 9: Global Active Pharmaceutical Ingredients Market Size and Forecast, By Drug Type (2019 to 2030F) (In USD Billion)
Table 10: South America Active Pharmaceutical Ingredients Market Size and Forecast, By Application (2019 to 2030F) (In USD Billion)
Table 11: South America Active Pharmaceutical Ingredients Market Size and Forecast, By Synthesis Type (2019 to 2030F) (In USD Billion)
Table 12: South America Active Pharmaceutical Ingredients Market Size and Forecast, By Type of Manufacture (2019 to 2030F) (In USD Billion)
Table 13: Influencing Factors for Active Pharmaceutical Ingredients Market, 2024
Table 14: Brazil Active Pharmaceutical Ingredients Market Size and Forecast By Application (2019 to 2030F) (In USD Billion)
Table 15: Brazil Active Pharmaceutical Ingredients Market Size and Forecast By Synthesis Type (2019 to 2030F) (In USD Billion)
Table 16: Brazil Active Pharmaceutical Ingredients Market Size and Forecast By Type of Manufacture (2019 to 2030F) (In USD Billion)
Table 17: Argentina Active Pharmaceutical Ingredients Market Size and Forecast By Application (2019 to 2030F) (In USD Billion)
Table 18: Argentina Active Pharmaceutical Ingredients Market Size and Forecast By Synthesis Type (2019 to 2030F) (In USD Billion)
Table 19: Argentina Active Pharmaceutical Ingredients Market Size and Forecast By Type of Manufacture (2019 to 2030F) (In USD Billion)
Table 20: Colombia Active Pharmaceutical Ingredients Market Size and Forecast By Application (2019 to 2030F) (In USD Billion)
Table 21: Colombia Active Pharmaceutical Ingredients Market Size and Forecast By Synthesis Type (2019 to 2030F) (In USD Billion)
Table 22: Colombia Active Pharmaceutical Ingredients Market Size and Forecast By Type of Manufacture (2019 to 2030F) (In USD Billion)

Figure 1: Global Active Pharmaceutical Ingredients Market Size (USD Billion) By Region, 2024 & 2030
Figure 2: Market attractiveness Index, By Region 2030
Figure 3: Market attractiveness Index, By Segment 2030
Figure 4: Global Active Pharmaceutical Ingredients Market Size By Value (2019, 2024 & 2030F) (in USD Billion)
Figure 5: Global Active Pharmaceutical Ingredients Market Share By Region (2024)
Figure 6: South America Active Pharmaceutical Ingredients Market Size By Value (2019, 2024 & 2030F) (in USD Billion)
Figure 7: South America Active Pharmaceutical Ingredients Market Share By Country (2024)
Figure 8: Brazil Active Pharmaceutical Ingredients Market Size By Value (2019, 2024 & 2030F) (in USD Billion)
Figure 9: Argentina Active Pharmaceutical Ingredients Market Size By Value (2019, 2024 & 2030F) (in USD Billion)
Figure 10: Columbia Active Pharmaceutical Ingredients Market Size By Value (2019, 2024 & 2030F) (in USD Billion)
Figure 11: Competitive Dashboard of top 5 players, 2024
Figure 12: Porter's Five Forces of Global Active Pharmaceutical Ingredients Market

Market Research FAQs

Domestic market is expected to grow 3times in the next decade. domestic pharmaceutical market is at US$ 42 billion in 2021 and likely to reach USD 65 billion by 2024 and further expand to reach USD 120-130 billion by 20

Active Pharmaceutical Ingredients market places aggregate APIs and provide a place for application developers to upload, distribute, and monetize their APIs while also providing a space for consumers to discover and implement APIs for their own products.

 Propaganda Cum Distribution. It is terminology often used in pharmaceutical marketing. Propaganda Cum Distribution highlights the right to market or distribute in the Pharmaceutical industry. A PCD Pharma franchise company provides the products to its entire branch franchise partner. .

The Code of Federal Regulations deals with governing of food and drugs in the United States for three of its governing bodies: Food and Drug Administration, Drug Enforcement Agency and Office of National Drug Control Policy.

Plants as the source of the highest medicines derived from the worldwide.
Logo

South America Active Pharmaceutical Ingredients (APIs) Market Outlook, 2030

Contact usWe are friendly and approachable, give us a call.